Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dsr Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active prosecution involves 1 distinct examiner and 1 distinct art unit, reflecting a singular focus for its current patent office interactions. In the competitive Biotechnology & Pharmaceuticals landscape, this single pending action represents the company's current front line for intellectual property protection. The concentration in 1 distinct art unit suggests that the company's technology is being evaluated against a specific set of prior art. This focus ensures that the examination is conducted by specialists familiar with the technical nuances of the company's innovations.
CHEN, CATHERYNE is the busiest examiner for the portfolio, holding the 1 pending office action. This single action represents the full extent of the company's current pending examination workload. Since the company is only dealing with 1 distinct examiner, the prosecution strategy can be highly personalized. Successfully resolving the 1 pending office action with CHEN, CATHERYNE is the primary objective for Dsr Corporation to advance its patent position in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033964 | MATRIX METALLOPROTEASE 1 EXPRESSION INHIBITOR, SKIN EXTERNAL AGENT, AND USE FOR INHIBITION OF MATRIX METALLOPROTEASE 1 EXPRESSION | CHEN, CATHERYNE | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033964 | MATRIX METALLOPROTEASE 1 EXPRESSION INHIBITOR, SKIN EXTERNAL AGENT, AND USE FOR INHIBITION OF MATRIX METALLOPROTEASE 1 EXPRESSION | CHEN, CATHERYNE | 1655 | §102 | Final Rejection | 46d overdue | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial